16.49

5.88% -1.03

Cullinan Therapeutics Inc (CGEM)

Overview News Price History Option Chain Financials Discussions Forecast

Cullinan Therapeutics Inc stock is traded at $16.49, with a volume of 701.84K. It is down -5.88% in the last 24 hours and down -9.45% over the past month. Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Previous Close:

$17.52

Open:

$17.52

24h Volume:

701.84K

Relative Volume:

0.69

Market Cap:

$1.01B

Revenue:

Net Income/Loss:

$-221.04M

P/E Ratio:

-4.4396

EPS:

-3.7143

Net Cash Flow:

$-178.65M

1W Performance:

-3.57%

1M Performance:

-9.45%

6M Performance:

+37.88%

1Y Performance:

+112.23%

1-Day Range:

$16.14

$17.52

1-Week Range:

$16.14

$17.99

52-Week Range:

$5.68

$19.43

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name

Cullinan Therapeutics Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

617-410-4650

Address

ONE MAIN STREET, CAMBRIDGE

Employee

109

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

CGEM's Discussions on Twitter

Compare CGEM vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEM Cullinan Therapeutics Inc	16.49	1.07B	0	-221.04M	-178.65M	-3.7143
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Initiated	Citigroup	Buy
Feb-02-26	Initiated	Guggenheim	Buy
Aug-21-25	Resumed	H.C. Wainwright	Buy
Jun-11-25	Resumed	Stifel	Buy
Oct-24-24	Initiated	UBS	Buy
May-01-24	Initiated	Stifel	Buy
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-02-21	Initiated	Evercore ISI	Outperform
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight
Feb-02-21	Initiated	SVB Leerink	Outperform
Feb-01-21	Initiated	H.C. Wainwright	Buy

View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

Jul 28, 2026

Cullinan Therapeutics stock rises on FDA meeting for CLN-049 By Investing.com - Investing.com Canada

Jul 28, 2026

Cullinan Therapeutics stock rises on FDA meeting for CLN-049 - Investing.com

Jul 28, 2026

Why is Cullinan Therapeutics stock climbing today? By Investing.com - Investing.com Canada

Jul 28, 2026

Cullinan Therapeutics (CGEM) Advances AML Treatment with FDA Fee - GuruFocus

Jul 28, 2026

Cullinan Therapeutics advances CLN-049 to Phase 2 after positive FDA feedback - Traders Union

Jul 28, 2026

Cullinan Therapeutics Announces Positive FDA Feedback for CLN-049 and Plans Potentially Registrational Phase 2 Study in Relapsed/Refractory AML - Quiver Quantitative

Jul 28, 2026

Cullinan Therapeutics Announces Positive End-of-Phase 1 - GlobeNewswire

Jul 28, 2026